Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.
The U.S. Food and Drug Administration approved Pfizer Inc.’s supplemental Biologics License Application for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).
A study published in the Nov. 2 edition of Cell suggests that pancreatic cancer cells avoid starvation by signaling to nerves, which encourages them to grow into dense tumors and release the nutrients the cells need to survive.
A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
A federal judge dismissed Catalyst Pharmaceuticals’ lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.
Genentech presented new data on Enspryng (satralizumab-mwge), which was approved by the U.S. Food and Drug Administration in mid-August 2020 as a subcutaneous treatment for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum.
Argenx announced positive topline results from the company’s Phase III ADAPT clinical trial of efgartigimod for myasthenia gravis.
Cambridge, Massachusetts-based Acceleron Pharma announced that the company’s Phase II clinical trial of ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) failed to show functional improvement.
Checkpoint Surgical Inc. – a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair – received Breakthrough Device designation from the U.S. Food and Drug Administration for the Checkpoint brief electrostimulation therapy (BEST) system.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.